{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:05:10Z","timestamp":1785503110164,"version":"3.56.0"},"reference-count":70,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/14760584.2026.2708199","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T12:28:01Z","timestamp":1785500881000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of RSVpreF for the prevention of respiratory syncytial virus illness among high-risk adults in Germany"],"prefix":"10.1080","volume":"25","author":[{"given":"Erin","family":"Quinn","sequence":"first","affiliation":[{"name":"Avalere Health","place":["Washington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"MacKinnon","sequence":"additional","affiliation":[{"name":"Avalere Health","place":["Washington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severin","family":"Freisberg","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5419-6059","authenticated-orcid":false,"given":"Caroline","family":"Lade","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Friedrich","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea J.","family":"Bayer","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"von Eiff","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahuva","family":"Averin","sequence":"additional","affiliation":[{"name":"Avalere Health","place":["Washington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Sato","sequence":"additional","affiliation":[{"name":"HTA, Value and Evidence, Pfizer Inc., Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Schiffner-Rohe","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2389676"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-01006-0"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2514357"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-00951-0"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1218-z"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2023.07.007"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00758-5"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac300"},{"key":"e_1_3_7_10_1","unstructured":"European Medicines Agency: Abrysvo [Internet]. 2025. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abrysvo#ema-inpage-item-authorisation-details"},{"key":"e_1_3_7_11_1","unstructured":"European Medicines Agency: Arexvy [Internet]. 2025. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/arexvy"},{"key":"e_1_3_7_12_1","unstructured":"European Medicines Agency: mRESVIA [Internet]. 2025. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mresvia"},{"issue":"32","key":"e_1_3_7_13_1","first-page":"3","article-title":"Beschluss und Wissenschaftliche Begr\u00fcndung zur Empfehlung der STIKO f\u00fcr eine Standardimpfung gegen Erkrankungen durch Respiratorische Synzytial-Viren (RSV) f\u00fcr Personen \u2265 75 Jahre sowie zur Indikationsimpfung von Personen im Alter von 60 bis 74 Jahren mit Risikofaktoren","volume":"2024","author":"Falman A","year":"2024","unstructured":"Falman A, Sch\u00f6nfeld V, Flasche S, et al. Beschluss und Wissenschaftliche Begr\u00fcndung zur Empfehlung der STIKO f\u00fcr eine Standardimpfung gegen Erkrankungen durch Respiratorische Synzytial-Viren (RSV) f\u00fcr Personen \u2265 75 Jahre sowie zur Indikationsimpfung von Personen im Alter von 60 bis 74 Jahren mit Risikofaktoren. Epidemiologisches Bull. 2024;2024(32):3\u201328.","journal-title":"Epidemiologisches Bull"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-026-01379-4"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-025-00565-3"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-017-2555-4"},{"key":"e_1_3_7_17_1","unstructured":"Vaccination for people who are immunocompromised [Available from: https:\/\/immunisationhandbook.health.gov.au\/contents\/vaccination-for-special-risk-groups\/vaccination-for-people-who-are-immunocompromised"},{"key":"e_1_3_7_18_1","unstructured":"Adult Immunization Schedule by Medical Condition and Other Indication [Internet]. Centers for Disease Control and Prevention. 2025. Available from: https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-schedules\/adult-medical-condition"},{"key":"e_1_3_7_19_1","volume-title":"Immunisation of individuals with underlying medical conditions: the green book, chapter 7","author":"UK Health Security Agency","year":"2020","unstructured":"UK Health Security Agency. Immunisation of individuals with underlying medical conditions: the green book, chapter 7. London, UK: GOV.UK; 2020."},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-023-02141-5"},{"key":"e_1_3_7_21_1","unstructured":"Deutsche Gesellschaft f\u00fcr Pneumologie und B. Positionspapier zur Impfung gegen Respiratorisches Synzytialvirus (RSV) bei Erwachsenen. 2023."},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-026-06769-9"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2024.2436183"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0335-2"},{"key":"e_1_3_7_25_1","unstructured":"Robert Koch-Institut. Modelling methods for predicting epidemiological and health economic effects of vaccinations. Guidance for analyses to be presented to the German Standing committee on vaccination (STIKO). 2024."},{"key":"e_1_3_7_26_1","unstructured":"Population on 1 January by age and sex [Internet]. Eurostat. 2025 [Available from: https:\/\/ec.europa.eu\/eurostat"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13054"},{"key":"e_1_3_7_28_1","unstructured":"Bericht zur Epidemiologie der Influenza in Deutschland Saison 2018\/19. 2020; 47[p. 22 p.]. Available from: https:\/\/influenza.rki.de\/saisonberichte\/2018.pdf"},{"key":"e_1_3_7_29_1","unstructured":"Goerlitz L Tolksdorf K Prahm K et al. ARE-Konsultationsinzidenz [Internet]. Geneva: Zenodo; 2025 Available from: https:\/\/zenodo.org\/records\/21127152"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-024-02391-x"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-023-02122-8"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106476"},{"key":"e_1_3_7_33_1","unstructured":"Deaths - number of cases by days weeks months age groups sex and federal states for Germany 2021\u20132025 [Internet]. Statistisches Bundesamt (Destatis). 2025. Available from: http:\/\/www.destatis.de\/EN\/"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2023.2262575"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2022.2134120"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2026.101520"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf061"},{"key":"e_1_3_7_38_1","unstructured":"Verbraucherpreisindex und Inflationsrate [Internet]. Statistisches Bundesamt (Destatis). 2025. Available from: https:\/\/www.de.statis.de\/EN\/"},{"key":"e_1_3_7_39_1","unstructured":"Abrysvo: LAUER-TAXE\u00ae [Internet]. 2023. Available from: https:\/\/www.cgm.com\/deu_de\/produkte\/apotheke\/lauer-taxe-en.html"},{"key":"e_1_3_7_40_1","unstructured":"Kassen\u00e4rztliche Vereinigung Westfalen-Lippe. Dokumentationsnummern und Verg\u00fctungen f\u00fcr Westfalen-Lippe. 2025. https:\/\/www.kvwl.de\/fileadmin\/user_upload\/pdf\/Mitglieder\/Rechtsquellen_und_Vertraege\/Impfvereinbarung\/Anhang_1_Stand_01052026.pdf"},{"key":"e_1_3_7_41_1","unstructured":"Average gross monthly earnings [Internet]. Statistisches Bundesamt (Destatis). 2024. Available from: https:\/\/www.desttatis.de\/EN\/"},{"key":"e_1_3_7_42_1","unstructured":"Employment rates by sex age and citizenship (%) [Internet]. Eurostat. 2024. Available from: http:\/\/ec.europa.eu\/eurostat"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.08.812"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12903"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac069"},{"key":"e_1_3_7_46_1","unstructured":"Influenza: standard vaccinations for adults and vaccinations for specific indications [Internet]. The Robert Koch Institute; 2025. Available from: https:\/\/public.data.rki.de\/t\/public\/views\/VacMap\/Erw_Maindashboard?%3Aembed=y&%3Atabs=n"},{"key":"e_1_3_7_47_1","unstructured":"Statutory health insurance (SHI). Internet. Federal Ministry of Health (Bundesministerium f\u00fcr Gesundheit); 2025. Available from: https:\/\/www.bundesgesundheitsministerium.de\/en\/themen\/krankenversicherung\/online-ratgeber-krankenversicherung\/krankenversicherung\/statutory-health-insurance-shi"},{"key":"e_1_3_7_48_1","unstructured":"Robert Koch-Institut. Epidemiologisches Bulletin 35\/2013. 2013. Available from: https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2013\/Ausgaben\/35_13.pdf"},{"key":"e_1_3_7_49_1","unstructured":"Robert Koch-Institut. Epidemiologisches Bulletin 26\/2018. 2018. Available from: http:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2018\/Ausgaben\/26_18.pdf"},{"key":"e_1_3_7_50_1","unstructured":"Robert Koch-Institut. Epidemiologisches Bulletin 50\/2018. 2018. Available from: https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2018\/Ausgaben\/50_18.pdf"},{"key":"e_1_3_7_51_1","unstructured":"Robert Koch-Institut. Epidemiologisches Bulletin 13\/2020. 2020. Available from: https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2020\/Ausgaben\/13_20.pdf"},{"key":"e_1_3_7_52_1","unstructured":"Robert Koch-Institut. Epidemiologisches Bulletin 1\/2021. 2021. Available from: https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2021\/Ausgaben\/01_21.pdf"},{"key":"e_1_3_7_53_1","unstructured":"Robert Koch-Institut. Epidemiologisches Bulletin 39\/2023. 2023. Available from: https:\/\/gpk.de\/downloadp\/STIKO_2023_Bulletin_KW_39_STIKO-Aktualisierung-der-Empfehlungen-zur-Pneumokokken-Impfung.pdf"},{"key":"e_1_3_7_54_1","unstructured":"Robert Koch-Institut. Epidemiologisches Bulletin 3\/2024. 2024. Available from: https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2018\/Ausgaben\/26_18.pdf"},{"key":"e_1_3_7_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213836"},{"key":"e_1_3_7_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.15896"},{"key":"e_1_3_7_57_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.15405"},{"key":"e_1_3_7_58_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2025.2539887"},{"key":"e_1_3_7_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126390"},{"key":"e_1_3_7_60_1","unstructured":"Robert Koch-Institut. Epidemiological Bulletin 4\/2025. Recommendations by the Standing Committee on vaccination (STIKO) at the Robert Koch institute \u2013 2025. 2025;29. https:\/\/www.rki.de\/EN\/Topics\/Infectious-diseases\/Immunisation\/STIKO\/STIKO-recommendations\/Downloads\/04_25_english.pdf?__blob=publicationFile&v=2"},{"key":"e_1_3_7_61_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.34579"},{"key":"e_1_3_7_62_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07736-1"},{"key":"e_1_3_7_63_1","unstructured":"Advisory Committee on Immunization Practices. EtR framework for adults aged 50\u201364 years who Currently do not have a risk-based pneumococcal vaccine indication. Centers for Disease Control and Prevention; 2024. Available from: https:\/\/www.cdc.gov\/acip\/evidence-to-recommendations\/pcv21-non-risk-based-adults-50-64-etr.html"},{"key":"e_1_3_7_64_1","volume-title":"Meeting of the ACIP","author":"Melgar M","year":"2022","unstructured":"Melgar M. ACIP adult RSV work group considerations. In: Meeting of the ACIP; Atlanta, GA; 2022."},{"key":"e_1_3_7_65_1","unstructured":"Persons in need of long-term care: Germany reference date sex age groups type of care given to those needing long-term care (22421\u20130001) [Internet]. Statistisches Bundesamt (Destatis). 2023 [Available from: https:\/\/www.destatis.de\/EN\/"},{"key":"e_1_3_7_66_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-025-12342-3"},{"key":"e_1_3_7_67_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268818000997"},{"key":"e_1_3_7_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.013"},{"key":"e_1_3_7_69_1","unstructured":"Ubamadu E Betancur E Curcio D et al. Respiratory syncytial virus sequelae among adults in high-income countries: a systematic literature review. International RSV symposium. Belfast (UK); 2022."},{"key":"e_1_3_7_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab491"},{"key":"e_1_3_7_71_1","unstructured":"Griskaitis M Sch\u00f6nfeld V Harder T et al. Vergleich von Impfstrategien zur Pr\u00e4vention von Erkrankung durch Respiratorische Synzytial-Viren: Auswirkungen auf Krankheitslast und Kosten (VIPER). Robert Koch-Institut. 2024."}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2026.2708199","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14760584.2026.2708199","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2026.2708199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T12:28:07Z","timestamp":1785500887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14760584.2026.2708199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/14760584.2026.2708199"],"URL":"https:\/\/doi.org\/10.1080\/14760584.2026.2708199","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2708199"}}